Compare AstraZeneca plc (AZN) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Southwest Airlines Co — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Southwest Airlines Co trades at $49.11 (market cap $23.25B). The key difference: AstraZeneca plc is far larger — about 10.9× Southwest Airlines Co's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | LUV | |
|---|---|---|
Market Cap | $253.13B | $23.25B |
Sector | Health | Industrials |
52-Week High | $209.48 | $54.80 |
52-Week Low | $137.44 | $29.06 |
Enterprise Value | $279.37B | $26.31B |
Dividend Yield | 1.92% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Southwest Airlines (LUV) trades at $47.92, down 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.47 suggesting upside. Recent earnings show a mix of beats and a miss, with Q2 2026 results expected soon. The company maintains a solid balance sheet with a debt-to-asset ratio improving to 16.86% in 2025, though net cash flow remains negative due to significant financing activities.
The outlook is cautiously optimistic, driven by potential earnings growth and cost management, but risks include fuel price volatility and competitive pressures. Analyst sentiment is mixed, with 42% buy ratings, highlighting both recovery potential and near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
